Skip to content

Trial · Interventional

CompletedPhase 4Results postedRegistry data

Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

NCTNCT05533632 (opens ClinicalTrials.gov in a new tab)Other idNN9535-4844Other idU1111-1281-5677
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 4
Enrollment
104 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Allocation not applicable · Open label (no masking)
Countries
1 country

Chile

Start
25 Apr 2022
Primary completion
18 Jan 2024
Completion
18 Jan 2024
First posted
9 Sept 2022
Last update posted
24 Sept 2025
Conditions
Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed · 1 with posted results

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2022202320242025
  1. Ph 4

    Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

    NCT05533632

    25 Apr 2022 to 18 Jan 2024

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

Interventions

  • SemaglutideDrug

Arms1

  • Experimental

    Semaglutide

    Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Number of Adverse Events (AEs)

    Time frame · From baseline (Day 1) up to 24 weeks

    Registry description

    Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Secondary outcomes(20)

  1. Change in Glycosylated Haemoglobin (HbA1c)

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in glycosylated haemoglobin (HbA1c) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  2. Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]

    Time frame · From baseline (week 1) to week 24

    Registry description

    Participants achieving HbA1c less than 7.0% (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  3. Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in fasting plasma glucose (FPG) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  4. Change in Body Weight (Kilogram [Kg])

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in body weight from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  5. Change in Waist Circumference [Centimeter (cm)]

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in waist circumference from baseline (week 1) to week 24 is presented. Waist circumference is defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  6. Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Participants achieving greater than or equal (≥) 5% weight reduction (Yes/No) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  7. Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Participants achieving greater than or equal (≥) 10% weight reduction (Yes/No) from baseline (week 1) to week is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  8. Change in Total Cholesterol (mg/dL)

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in total cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  9. Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in low density lipoprotein (LDL) cholesterol (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  10. Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in high density lipoprotein (HDL) cholesterol (mg/dL) cholesterol from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  11. Change in Triglycerides (mg/dL)

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in triglycerides (mg/dL) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  12. Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)]

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in estimated glomerular filtration rate (eGFR) \[millilitre per minute (mL/min) per 1.73 square meter (m\^2)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  13. Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)]

    Time frame · Baseline (week 1), week 24

    Registry description

    Change in Urine Albumin-Creatinine Ratio (UACR) \[milligram per gram (mg/g)\] from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), premature discontinuation follow-up visit.

  14. Participants Discontinued Due to Adverse Events (Treatment Discontinuation)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Participants discontinued due to adverse events (treatment discontinuation) from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

  15. Number of Severe Hypoglycaemic Episodes

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of severe hypoglycaemic episodes from baseline (week 1) to week 24 is presented. Hypoglycaemic episodes were classified as severe if there was no specific glucose threshold but were associated with severe cognitive impairment requiring external assistance for recovery. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

  16. Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of severe or blood glucose confirmed symptomatic hypoglycaemic episodes from baseline (week 1) to week 24 is presented. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period starts at the date of first dose of study product and ends at any of the following: end of treatment (week 24), follow-up visit, premature discontinuation follow-up visit.

  17. Number of Serious Adverse Events (SAEs)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of serious adverse events (SAEs) from baseline (week 1) to week 24 is presented. An SAE is any untoward medical occurrence that fulfils at least one of the following criteria: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; important medical event. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

  18. Number of Adverse Reactions (ARs)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of adverse reactions (ARs) from baseline (week 1) to week 24 is presented. Adverse reaction is an undesired effect of a drug or other type of treatment that can range from mild to severe and can be life-threatening. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

  19. Number of Serious Adverse Reactions (SARs)

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of serious adverse reactions (SARs) from baseline (week 1) to week 24 is presented. Serious adverse reaction is an adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

  20. Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant

    Time frame · From baseline (week 1) to week 24

    Registry description

    Number of suspected unexpected serious adverse reactions (SUSARs) per participant from baseline (week 1) to week 24 is presented. SUSAR is a serious adverse event which is unexpected and regarded as possibly or probably related to the trial product. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as the time period where sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

Primary outcome results

Primary outcomeNumber· From baseline (Day 1) up to 24 weeks

Number of Adverse Events (AEs)

GroupValue (Events)
Semaglutide45
Secondary and other outcome results(7)
Secondary outcomeMean· Baseline (week 1), week 24

Change in Glycosylated Haemoglobin (HbA1c)

GroupValue (Percentage of HbA1c)Spread
Semaglutide-1.61.0
Secondary outcomeCount of participants· From baseline (week 1) to week 24

Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No]

GroupValue (Participants)
Semaglutide52
Secondary outcomeMean· Baseline (week 1), week 24

Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)]

GroupValue (mg/dL)Spread
Semaglutide-26.261.3
Secondary outcomeMean· Baseline (week 1), week 24

Change in Body Weight (Kilogram [Kg])

GroupValue (Kg)Spread
Semaglutide-5.34.3
Secondary outcomeMean· Baseline (week 1), week 24

Change in Waist Circumference [Centimeter (cm)]

GroupValue (cm)Spread
Semaglutide-5.75.7
Secondary outcomeCount of participants· From baseline (week 1) to week 24

Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)

GroupValue (Participants)
Semaglutide56
Secondary outcomeCount of participants· From baseline (week 1) to week 24

Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)

GroupValue (Participants)
Semaglutide17

Adverse events, as posted

Adverse events as posted: participants affected out of participants at risk, by group
GroupDeathsSerious eventsOther events
SemaglutideParticipants received subcutaneous (s.c.) injection of Semaglutide once-weekly in a dose escalation manner for 24 weeks: 0.25 milligrams \[mg\], (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).0 / 1041 / 10418 / 104

Each cell reads participants affected / participants at risk, as the registry posted them.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit. * Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit. * HbA1c 7.5-10% (59-86 millimoles per mole \[mmol/mol\]) (both inclusive) in Visit 1. * Participants in which Ozempic is indicated according to approved local label. * Fundoscopy/Fundus photography record less than equal to (≤) 12 months. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Previous participation in this study. Participation is defined as signed informed consent. * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method. * Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed). * Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit. * Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma. * History of pancreatitis (acute or chronic). * Renal impairment defined as estimated glomerular filtration rate (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m\^2) as per MDRD-4 (Modification of Diet in Renal Disease). * Myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening. * Participants presently classified as being in New York Heart Association (NYHA) Class IV heart failure. * Planned coronary, carotid or peripheral artery revascularisation known on the day of screening. * Participants with alanine aminotransferase (ALT) \> 2.5 x upper normal limit (UNL). * Use of systemic immunosuppressive treatment within 90 days prior to screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days. * Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator. * Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening. * History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).

PepBank is a research reference. Talk to a doctor before you use any peptide.